AC3056
Initial focus on prevention of restenosis
- Potential target treatment for atherosclerosis
Licensed from Aventis Pharma (HMR)
- Aventis option to partner at end of Phase 2
Three modes of action shown in animals:
- Inhibition of cell adhesion molecules in vascular cells
- Inhibition of lipoprotein oxidation
- Lowering of serum LDL but not HDL
First Phase 1 study demonstrated:
- Orally bioavailable with no safety concerns noted
Additional Phase 1 studies planned